Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2024-04-12
2024-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to demonstrate that different types of blood samples (finger prick, venous whole blood and plasma) return comparable results when analysed using the SpinChip hs-cTnI test. Blood samples from at least 150 patients will be analyzed and the testing will be carried out by healthcare personnel.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SpinChip Hs-cTnI Multisite Precision
NCT06851013
SpinChip Hs-cTnI Clinical Diagnostic Performance
NCT06499519
SpinChip Hs-cTnI Determination of the 99th Percentile URL
NCT06463275
Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes
NCT02060760
Use of High Sensitivity Cardiac Troponin in Ruling Out Emergency Patients with Acute Myocardial Injury and Infarction
NCT04280926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During a heart attack, cardiac muscle cells are injured and release the cardiac marker troponin I (cTnI) into the bloodstream. High-sensitive troponin tests may detect the increase of cardiac troponin in blood within hours after the symptoms of a heart attack has started.
The SpinChip high-sensitivity cardiac troponin I (hs-cTnI) test is a new high-sensitive test for measuring troponin I in blood samples, and the analysis may be performed close to the patient (near-patient test). The results may be obtained within 10 minutes, compared to approximately 1 hour for normal laboratory analysis.
The SpinChip Platform consists of the SpinChip hs-cTnI test and the SpinChip Analyzer and may be used at the emergency department to evaluate patients presenting with symptoms of acute myocardial infarction (chest pain). The test can use blood from finger prick or venous blood samples, either as whole blood or separated into plasma.
The purpose of this study is to demonstrate that different sample types (finger prick, venous whole blood or plasma) give comparable results when analysed using the SpinChip hs-cTnI test when the testing is performed by healthcare professionals. Samples from minimum 150 patients with troponin levels covering the measuring range of the SpinChip hs-cTnI test will be collected and analysed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SpinChip hs-cTnI
SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects \>18 years old
* Clinical cardiac Troponin T concentration available
Exclusion Criteria
* Self-reported pregnancy
* General clinical condition which affects the patient in a major way and the patient is considered to be in an unstable clinical condition
* Previously included in the study with a sample within the measuring range of the SpinChip hs-cTnI test
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aurevia
INDUSTRY
University Hospital, Akershus
OTHER
SpinChip Diagnostics ASA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helge Røsjø, MD/Professor
Role: PRINCIPAL_INVESTIGATOR
Akershus University Hospital, Akershus Clinical Research Center (ACR)
Gro Leite Størvold, PhD
Role: STUDY_DIRECTOR
SpinChip Diagnostics ASA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akershus University hospital, Akershus Clinical Research Center (ACR)
Lørenskog, Akershus, Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIV-NO-24-01-045754
Identifier Type: OTHER
Identifier Source: secondary_id
Design Protocol-03645
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.